HUMACYTE INC. - COMMO

Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program

15 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte Second Quarter 2023 Financial Results and Business Update

14 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 14, 2023

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel™ (HAV™)

03 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair

26 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte to Present at the Jefferies Healthcare Conference

05 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Humacyte First Quarter 2023 Financial Results and Business Update

12 May 2023 06:05:00 By Nasdaq GlobeNewswire

Humacyte and Oberland Capital Announce Funding Arrangement Totaling Up to $160 Million

12 May 2023 06:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Publication in Lancet Regional Health - Europe Presenting Use of Human Acellular Vessel™ (HAV™) to Treat Vascular Injuries in Ukraine

09 May 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023

05 May 2023 07:00:00 By Nasdaq GlobeNewswire

Humacyte’s Human Acellular Vessel™ (HAV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma

04 May 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

28 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes

27 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte Announces Publication of Preclinical Study Comparing Human Acellular Vessel™ (HAV™) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma

18 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients

11 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update

24 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023

21 Mar 2023 07:01:00 By Nasdaq GlobeNewswire

Humacyte to Present at Upcoming Investor Conferences in March

27 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease

24 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime

13 Dec 2022 07:00:02 By Nasdaq GlobeNewswire